Bluelake Biotechnology 10/28/26 Bluelake Biotechnology 10/28/26

Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate

Bluelake Biotechnology 10/12/26 Bluelake Biotechnology 10/12/26

Blue Lake Biotechnology to Present Data for RSV Vaccine Candidate BLB201 in a Late-Breaking Presentation at ISV Annual Congress

Bluelake Biotechnology 11/21/25 Bluelake Biotechnology 11/21/25

Blue Lake Biotechnology to Resume Enrollment of RSV-negative Toddlers in Phase 1/2a Clinical Trial of BLB201

Bluelake Biotechnology 7/7/25 Bluelake Biotechnology 7/7/25

Blue Lake and CyanVac Publish Full Data from Open Label Phase 1 Clinical Study of COVID-19 Vaccine Candidate

Research published in Science Advances indicate that CVXGA is a promising intranasal vaccine candidate that is safe, immunogenic and potentially effective with minimal reactogenicity

Bluelake Biotechnology 7/4/25 Bluelake Biotechnology 7/4/25

Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial

from Cincinnati Children’s Hospital Research Horizons

Bluelake Biotechnology 3/27/25 Bluelake Biotechnology 3/27/25

Preclinical Intranasal COVID-19 Vaccine Candidate Data Demonstrate Durable Immune Response and Broad Protection

Research published in Journal of Virology (publication #1) (publication #2)

Bluelake Biotechnology 3/10/25 Bluelake Biotechnology 3/10/25

Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium

Bluelake Biotechnology 12/12/24 Bluelake Biotechnology 12/12/24

Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201

Bluelake Biotechnology 12/9/24 Bluelake Biotechnology 12/9/24

First Subject Dosed in Initial Cohort of Phase 2b Clinical Study of CyanVac’s Intranasal COVID-19 Vaccine Candidate

Bluelake Biotechnology 11/25/24 Bluelake Biotechnology 11/25/24

Blue Lake and CyanVac Report Positive Phase 2a Data for Intranasal COVID-19 Vaccine Candidate

Bluelake Biotechnology 10/21/24 Bluelake Biotechnology 10/21/24

Blue Lake Biotechnology and CyanVac Announce Presentation on Intranasal Vaccine Candidates at the International Society for Vaccines Annual Congress

Bluelake Biotechnology 6/13/24 Bluelake Biotechnology 6/13/24

CyanVac Receives BARDA-Funded Project NextGen Award to Evaluate its Intranasal COVID-19 Vaccine Candidate in a Phase 2b Study

Bluelake Biotechnology 3/21/24 Bluelake Biotechnology 3/21/24

Blue Lake Biotechnology reports positive interim clinical data in children for its RSV vaccine candidate

Bluelake Biotechnology 2/15/24 Bluelake Biotechnology 2/15/24

Preclinical Data on PIV5-based Intranasal Vaccine Against Lyme Disease Demonstrates Durable Immune Response

Research published in NPJ Vaccines

Bluelake Biotechnology 10/25/23 Bluelake Biotechnology 10/25/23

Positive Phase 1 Data for Blue Lake Biotechnology’s Intranasal RSV Vaccine Published in Science Advances

Positive Phase 1 Data for Blue Lake Biotechnology’s Intranasal RSV Vaccine Published in Science Advances

Bluelake Biotechnology 9/27/23 Bluelake Biotechnology 9/27/23

Blue Lake Biotechnology Presenting at Upcoming BioFuture and BIO Investor Forum Conferences

Bluelake Biotechnology 9/21/23 Bluelake Biotechnology 9/21/23

From Setbacks to Solutions: Pioneering Safe RSV Vaccines for Infants, Children

article by founder Biao He in Pharmacy Times

Bluelake Biotechnology 6/29/23 Bluelake Biotechnology 6/29/23

Blue Lake Biotechnology Doses First Child in Clinical Trial of Novel Intranasal Vaccine Against Respiratory Syncytial Virus

Bluelake Biotechnology 5/31/23 Bluelake Biotechnology 5/31/23

Blue Lake Biotechnology to Be Featured at the Biotechnology Innovation Organization (BIO) International Convention

Bluelake Biotechnology 3/15/23 Bluelake Biotechnology 3/15/23

How a nasal vaccine could reduce the risk of COVID infections — and new variants

from MarketWatch